Reposted by: Mark P. Lythgoe
rdcu.be/d49Ol
@trends in #Cancer
www.cell.com/trends/cance...
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
Reposted by: Mark P. Lythgoe, Arash Rashidian, Franz Essl , and 17 more Mark P. Lythgoe, Arash Rashidian, Franz Essl, James P. Collins, Mike S. Schäfer, John Newman, Lisa M. Given, Andrew Taylor, Francisco Rowe, Merijn Chamon, Siân E. Halcrow, Daniel Vogler, Bhuva Narayan, Joy Parkinson, Lorenzo Álvarez‐Filip, Eunji Kim, Lucy Lu Wang, Manuel Ramírez-Sánchez, Beatriz Goulão, Richard Berry
A Place of Joy.
#nature
about #SONIA trial challenging frontline CDK4/6 use in #breastcancer - does this have implications for practice today?
www.nature.com/articles/s41...
Reposted by: Mark P. Lythgoe
Reposted by: Mark P. Lythgoe
What's behind the problems and what are countries doing about it?
www.bmj.com/content/387/...